FeesSafety
Pluang+

Leonardo DRS Q3 2026 revenue rises 11%, net earnings up 60%, boosts 2026 outlook and declares dividend.

Company Fundamentals
29 Oct 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Leonardo DRS Q3 2026 revenue rises 11%, net earnings up 60%, boosts 2026 outlook and declares dividend.

Leonardo DRS reported strong Q3 2026 results with revenue up 11% to $1.1 billion and net earnings soaring 60% to $115 million, driven by growth in tactical radars, naval power, and space sensing programs. Adjusted EBITDA rose 27%, and the company achieved a record funded backlog of $5.6 billion, up 21% year-over-year. The robust bookings and backlog support a raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS. Leonardo DRS also declared a cash dividend of $0.09 per share payable in November, reflecting confidence in ongoing growth and cash flow generation.

Leonardo DRS's Q3 2026 financial results provide context for readers interested in industrials. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 17:53 WIB: out of 135 priced stocks, 76 rose and 57 fell. Notable movers include Caterpillar Inc (CAT) at USD 649.18 with a 1-day change of -9.00%, Howmet Aerospace Inc (HWM) at USD 210.48 up 7.76%, and FTAI Aviation Ltd (FTAI) at USD 180.00 up 7.69%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App